Management goals for type 1 Gaucher disease: An expert consensus document from the European working group on Gaucher disease.
Biegstraaten M, Cox TM, Belmatoug N, et al. Blood Cells Mol Dis. 2018;68:203-208.
Guidelines for the restart of imiglucerase in patients with Gaucher disease: recommendations from the European Working Group on Gaucher disease.
Hollak CE, Aerts JM, Belmatoug N, et al. Blood Cells Mol Dis. 2010;44(2):86-7.
Force majeure: therapeutic measures in response to restricted supply of imiglucerase (Cerezyme) for patients with Gaucher disease.
Hollak CE1, vom Dahl S, Aerts JM, et al. Blood Cells Mol Dis. 2010;44(1):41-7.
The role of the iminosugar N-butyldeoxynojirimycin (miglustat) in the management of type I (non-neuronopathic) Gaucher disease: a position statement.
Cox TM, Aerts JM, Andria G, et al. J Inherit Metab Dis. 2003;26(6):513-26.
Management of neuronopathic Gaucher disease: a European consensus.
Vellodi A, Bembi B, de Villemeur et al. J Inherit Metab Dis. 2001 Jun;24(3):319-27.
